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Summary.-Urinary aetiocholanolone levels have been measured in 417 women
aged between 20 and 70 years. The women were drawn from South East Scotland
and South Wales and consisted of patients with either benign or malignant disease
of the breast and control patients suffering from no detectable breast disorder.
The pattern of aetiocholanolone excretion with respect to age and menopausal
status has been defined in each group of patients.
No significant differences in urinary levels have been detected between patients
with breast disease, whether benign or malignant, and control patients. More
detailed examination of the 201 women with early cancer of the breast has also
shown that there is no consistent correlation between pre-operative aetiocholanolone
levels and factors of prognostic significance detectable at the time of primary treat-
ment-tumour size, grade, round cell infiltration, histological involvement of nodes
by tumour and the clinical palpability of lymph nodes.
It would seem, therefore, that the prognostic value of pre-operative aetiocho-
lanolone measurements is somewhat limited in patients with early breast cancer.
It is noted, however, that low levels of aetiocholanolone are associated with post-
menopausal patients, a group in which the prognosis is generally poorer than that
in pre-menopausal women.
CONSIDERABLE interest in the relation- matched controls (Bulbrook, Hayward
ship ofurinary androgen metabolites with and Spicer, 1971).
breast cancer has been provoked by the Whilst it is now accepted that low
studies of Bulbrook and his colleagues aetiocholanolone levels are associated with
(Bulbrook et at., 1962). These workers a proportion of patients with advanced
have indicated that (a) some women with breast cancer who have a poor prognosis
advanced cancer have subnormal levels (Kumaoka et al., 1968; Cameron et al.,
of urinary aetiocholanolone and are un- 1970), the situation in patients with
likely to respond to major endocrine early disease remains equivocal, several
ablation (Atkins et al., 1968a, b); (b) a studies indicating that aetiocholanolone
proportion of women with early breast levels are normal in these women (Alquist,
cancer also have abnormally low aetio- Jackson and Stewart, 1968; Wade et
cholanolone levels (Bulbrook et al., 1962) al., 1969; Cameron et al., 1970). With
and that this is associated with poor the recent finding that C19 androgenic
prognosis (Hayward and Bulbrook, 1968); steroids may act as precursors for tumour
(c) " normal " women who subsequently growth promoting hormones (Miller and
develop breast cancer have lower mean Forrest, 1974), it is even more important
excretion of aetiocholanolone than to resolve this conflict.620 W. R. MILLER ET AL.
In an effort to do so, we have retro- Cancer patients.-There were 60 patients
spectively examined the results of urinary from Cardiffand 141 patients from Edinburgh
aetiocholanolone measurements performed with invasive carcinoma of the breast. All
in two major centres in normal women of these cases were deemed to have operable
and in patients with either early cancer
orearly cancer ofthe breast and themajority
orbengndisasofthbras.-Thsewere ofinternational olinical Stages I and II. Or benign dislese of the breast. These A few cases were in international clinical
have been analysed with regard to age Stage III, solely on account of a primary
and menopausal status, in order to define tumour of a size greater than 5 cm diameter.
the normal pattern ofexcretion in patients Menstrual status.-Each of the groups
and controls, and then related to other has been further divided according to their
factors ofknown prognostic significance. menstrual status, by the following criteria:
Pre-menopausal-patients with regular
menstrual periods;
PATIENTS AND METHODS Menopausal-patients whose periods were
Urine was obtained from 417 hospital diminishing in frequency or whose last
in-patients in Cardiff and Edinburgh. Pa- period was within 2 years of primary
tients were excluded from the study if they treatment;
had known endocrine disease, had been Post-menopausal -patients whose last
receiving steroid preparations of any type period had occurred more than 2 years . 1 . .fl . 1 ~~~~~before treatment. or had a history of cancer at any site other
than in the breast. Tumour grade.-Histological grade of the Control patients.-These were 23 women tumour was assessed in 191 of the
from Cardiff and 22 from Edinburgh who primary us thesseria of te
were admitted to hospital for elective surgery 01 paiet, using th teiasofiPateand for conditions not involving the breast. Scarf(1928 1929). In this classification
None was suspected of having malignant increasigrade reflects an increase in
disease of any kind. The majority were 1971u n m
to undergo cholecystectomy, but others Bound cell infiltration.-At the time of included patients awaiting surgery for her- . .
nias, duodenal ulcers and varicose veins.
These patients were therefore subjected to round cell infiltration was also carried out, These patients were therefore subjected to adsrbdb hmin alc n
similar pre-operative stress as subjects with
a X
breast disorders. Prescott (1972).
Benignbreaest disease.-The 163 women in Tumour size.-The clinical size of the Benign breast disease. 16 woe in tumour was measured by 2 independent
tigroupd by enigion dioses Note brtea observers at the time of presentation. The proved by exiso bipy No frthe tumour was measured in 2 planes at right-
histological classification of the 76 women
from Cardiff was made but the pathological angles and the larger diameter was recorded
records were checked to ensure that the in cm.
diagnosis of benign disease was correct. Lymph node involvement.-The clinical
Sufficient numbers of pre-menopausal status of the axillary nodes was assessed
women from Edinburgh with benign breast by 2 observers before operation. Micro-
disease were studied to subdivide this group scopical examination for the presence of
further. tumour was carried out in all cases from which lymph nodes had been removed.
Group 1-fibrocystic disease of the breast In Cardiff, where the standard operations
(17 patients) (those patients in whom the were either a simple mastectomy with
predominant histological abnormalities pectoral node biopsy or a modified radical
were the presence of fibrosis and cyst mastectomy, axillary node histology was
formation); available. In Edinburgh, where simple and
Group 2-epitheliosis (17 patients) (lesions radical mastectomies were performed, it
in which epitheliosis of a marked degree was possible to make a histological assess-
was present); ment of the radical mastectomy group only
Group 3-fibroadenomata (25 patients). (68 patients), no axillary nodes being avail-URINARY AETIOCHOLANOLONE IN PATIENTS WITH EARLY BREAST CANCER 621
able from those patients undergoing simple As statistical analysis of urinary ster-
mastectomy. oids with age revealed a log normal
Urine collection and analysis.-Urine was distribution (Cameron et al., 1970), aetio-
collected from all patients pre-operatively; cholanolone levels have been expressed
in Cardiff for 48 h and in Edinburgh for in logarithms to the base 10 of the con-
24 h before operation.
The techniques used for estimation of centration (ag/24 h)
aetiocholanolone were based on that de-
scribed by Thomas and Bulbrook (1964),
and Thomas (1965). Different modifications Scattergrams relating aetiocholanolone
of these basic methods were introduced levels to age and menopausal status in
separately in Cardiff (Cameron et al., 1970) the patients with early breast cancer,
and Edinburgh (Sneddon, 1969). These from Cardiff are shown in Fig. 1 and
variations have led to minor differences from Edinburgh in Fig. 2. These figures
between centres with respect to extraction, also show the regression lines of aetio-
purification and measurement of aetio-
c cholanolone, all of which are unlikely to colanopoesit age forpth pre-
affect quantitation. One major difference post-menopausal patient groups. The re-
between the methods employed in the gression coefficients for these lines do
2 centres, however, was the use of con- not differ significantly from zero. Ageper
jugated internal standards in Cardiff and se, therefore, has little effect on aetio-
free steroid standards in Edinburgh in order cholanolone excretion in patients from
to monitor manipulative losses. This is either city. There is, however, a signi-
likely to result in different absolute values ficant difference between the mean levels
for aetiocholanolone in any given specimen of aetiocholanolone in the pre- and post-
of urine. The results from the 2 centres * p
are therefore presented separately. Never- nau patnt s, ther betiong losb
theless, any differences in aetiocholanolone stantial reduction in aetiocholanolone
values between the centres ought to be excretion after the menopause.
consistent, and the same relationship between Analysis of the control and benign
aetiocholanolone and other parameters there- disease groups (restricted to 30 years
fore would be expected in results from both and older) also revealed a similar pattern.
Cardiff and Edinburgh. Once subdivided into pre- and post-
menopausal patients, age had no
significant effect on the level of urinary
RESULTS aetiocholanolone. The pre-menopausal
The mean and standard deviation for patients, however, showed significantly
the ages of the patient groups under increased levels compared with post-
study in Cardiff and Edinburgh is shown menopausal patients (Fig. 3, 4).
in Table I. The pre-menopausal, benign Information was available from a
and control groups from Cardiff are number of patients under the age of
considerably younger than the correspond- 30 years-15 patients with benign disease
ing cancer group. To achieve com- and 5 control patients from Cardiff.
parability, only individuals aged 30 or These data are included in Fig. 5 and 6,
more have been compared in the subse- which show the relationship between
quent tests of significance (see below). the aetiocholanolone excretion for all of
TABLE I.-Mean Age and Standard Deviation ofPatient Groups 'Under Study
Pre-menopausal Post-menopausal
A A , A
Cardiff Edinburgh Cardiff Edinburgh
Controls 33-O+12-3 39-147-3 63.1±7-2 607+5-0
Benign disease 35-6±8-7 403±5-4 500±5*2 57.06-3
Cancer 43-1±6-78 44-0±4-5 60-7±558 59 7±6 5622 W. R. MILLER ET AL.
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FIG. 1.-Scattergram relating aetiocholanolone levels to age and menopausal status in 60 patients with
early breast cancer from Cardiff.
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FIG. 2.-Scattergram relating aetiocholanolone levels to age and menopausal status in 141 patients
with early breast cancer from Edinburgh.
the pre-menopausal control patients and not apparent in the small number of
for those with benign breast disease. women in the control group.
In the benign group, there is a gradual . .
increase in aetiocholanolone levels up Variation with breast disease
to the age of 30 years, beyond which This information is presented in Fig.
the mean level of excretion becomes 3 and 4. Analysis of variance showed
relatively constant. This relationship is no significant difference in mean aetio-URINARY AETIOCHOLANOLONE IN PATIENTS WITH EARLY BREAST CANCER 623
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FIG. 3.-Urinary aetiocholanolone levels by menopausal status in control subjects and patients with
early breast cancer and benign breast disease from Cardiff (lines refer to mean i standard error
for the Groups).
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FIG. 4.-Urinary aetiocholanolone levels by menopausal status in control subjects and patients with
early breast cancer and benign breast disease from Edinburgh (lines refer mean + standard error
for the groups).
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FIG. 5.-Scattergram of aetiocholanolone levels against age in 58 premenopausal patients with
benign breast disease from Cardiff.
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cholanolone levels between benign, cancer undergoing radical mastectomy, from
and control patients, whether pre- or whom histological examination of nodes
post-menopausal, in women from either was possible.
Cardiff or Edinburgh. The further sub- No consistent correlation was found
division of the Edinburgh patients with between aetiocholanolone levels and any
benign breast disease into those with of these factors of prognostic significance.
fibroadenomata, fibroadenosis or epithe- Significant but diverging relationships
liosis, revealed no differences between were, however, observed in Cardiff and
these groups (Fig. 7). in the full Edinburgh series with regard
to both tumour grade and round cell
Correlatio with othinfiltration. No obvious reasons are ap- Correlation with other clinical and tumour parent for these paradoxical observations.
parameters
Size, malignancy grade and round cell DISCUSSION
infiltration of the primary tumour, to- Using data obtained separately from
gether with clinical palpability of lymph the 2 centres, it has been possible to
nodes, were assessed in 191 patients from define the excretion of aetiocholanolone
the 2 centres. Histological examination in control women and patients with
of lymph nodes was performed on 120 benign and malignant breast disease,
patients. The partial correlation coeffi- with respect to their age and menstrual
cients of aetiocholanolone with each of status. By examining the data from
the other variables are shown in I'able II. patients with early breast cancer, it has
also been possible to relate these aetio-
cholanolone levels to other factors known
TABLE II.-Partial Correlation Coefficients to be of prognostic significance.
of Aetiocholanolone and Variables of Therelationship betweenurinary aetio-
Possible Prognostic Significance cholanolone and age has previously been
Edinburgh expressed in the form of a quadratic
R Adical Total equation (Cameron et al., 1970), increasing
Cardiff mastectomy group age being associated with decreasing
(52 (68 (139 aetiocholanolone excretion. Whilst the
patients) patients) patients) present results are in accord with these
Grade -.30* 001 _0 19* findings, they also indicate that age per Round cell -0.30* 0.15 0.18* se is not associated with lowered aetio-
involvement cholanolone levels. If the results are
Clinical involve- 0.11 0 02 0.01 re-plotted after dividing the patients into ment
Histological 0*12 0 02 - pre- and post-menopausal groups, then
involvement age alone fails to influence urinary aetio-
Size 0.22* 0-07 0.01 cholanolone excretion significantly. It
*P < 0*05. seems, therefore, that the reduction in
aetiocholanolone observed with increasing
age is a result ofthe increasing proportion
These coefficients reflect the association of post-menopausal women. This rela-
between aetiocholanolone levels and each tionship is also observed in control
ofthese variables, after mutual association patients and in those with benign breast
with menopausal status and with each disease.
of the other variables, has been taken The present study, using a large
into account (Steel and Torrie, 1960). number of patients, confirms the findings
In the Edinburgh series, the full set of Wade et al. (1969) and Cameron et
of partial correlation coefficients could al. (1970) that the mean urinary aetio-
only be obtained for the 68 patients cholanolone levels of patients with early
43§626 W. R. MILLER ET AL.
breast cancer are no different from those
with either benign disease or in-patient
controls. The observation that patients
with epitheliosis (believed to be a pre-
malignant condition) have normal aetio-
cholanolone levels does not support the
suggestion that low aetiocholanolone levels
may occur in women susceptible to
breast cancer.
It has not been possible to demonstrate
any consistent relationship between pre-
operative urinary aetiocholanolone and
any single one of a series of clinical and
morphological factors of known prog-
nostic significance in women with early
breast cancer. These observations, there-
fore, are at variance with the suggestion
that aetiocholanolone is of major prog-
nostic significance in early breast cancer
(Hayward and Bulbrook, 1968). In this
respect, the time of the urine collection
may be of importance. The data in
the present study is based upon pre-
operative specimens whereas those in
Bulbrook's study related to urine collected
10 days after mastectomy. It is now
known that mastectomy, possibly via
the stress of surgical procedures, in-
fluences both urinary and plasma levels
of androgenic steroids (Hayward and
Bulbrook, 1968; Wang et al., 1974).
Conversely, patients awaiting surgery are
likely to suffer pre-operative stress and
this may also contribute to differences
in pre- and post-operative steroid excre-
tion.
It should be noted, however, that
this study shows one group of patients,
i.e. the post-menopausal women, who
are likely to have low urinary aetio-
cholanolone levels. It is therefore inter-
esting that pre-menopausal women over
35 years with breast cancer have a better
prognosis than those women who are
post-menopausal (Hamilton et al., 1974).
We therefore emphasize the importance
of menopausal status in early breast
cancer and suggest that it should be taken
into account when assessing the possible
predictive value of urinary aetiocho-
lanolone.
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